Curanex Pharmaceuticals Inc (CURX) Key Metrics
CURX valuation today
Trailing 12 months · as of October 17, 2026- Market cap
- $7.2M
- Enterprise value
- $4.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- —
- Price / book
- 1.5
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
CURX key metrics, 2022–2025
Fiscal year ended December 31, 2025 · U.S. dollarsCURX returns How much profit the business earns on the capital it uses.
CURX per-share figures Results divided by the shares outstanding at year-end.
CURX financial health Debt, liquidity and how easily interest is covered.
CURX valuation history
CURX returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CURX debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CURX price vs earnings per share
CURX key metrics
2022–2025| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Valuation | ||||
| Market capitalization | $9.4M | — | — | — |
| Enterprise value | $4.7M | — | — | — |
| Price / book | 0.8 | — | — | — |
| Earnings yield | −45.1% | — | — | — |
| Free cash flow yield | −111.9% | — | — | — |
| Share price at fiscal year-end | $6.61 | — | — | — |
| Per share | ||||
| Revenue per share | $0.00 | $0.00 | $0.00 | $0.02 |
| Earnings per share | −$2.98 | −$0.26 | −$0.01 | −$0.01 |
| Operating cash flow per share | −$7.40 | −$0.40 | −$0.00 | $0.00 |
| Free cash flow per share | −$7.40 | −$0.40 | −$0.00 | $0.00 |
| Cash per share | $3.51 | $0.11 | $0.05 | $0.00 |
| Book value per share | $7.92 | $0.36 | $0.04 | $0.01 |
| Tangible book value per share | $7.92 | $0.36 | $0.04 | $0.01 |
| Capex per share | $0.00 | $0.00 | $0.00 | $0.00 |
| Debt per share | $0.24 | — | — | — |
| Shares outstanding | 1.4M | 1.4M | 1.4M | 1.4M |
| Change in shares outstanding | +2.1% | 0.0% | 0.0% | — |
| Returns & profitability | ||||
| Return on equity (ROE) | −72.1% | −128.3% | −54.6% | −197.7% |
| Return on invested capital (ROIC) | −96.4% | −169.6% | — | −204.9% |
| Return on assets (ROA) | −69.8% | −122.1% | −45.4% | −197.7% |
| Return on tangible assets | −36.5% | −69.8% | −25.8% | −197.7% |
| Free cash flow margin | — | — | — | 12.8% |
| Financial health | ||||
| Total debt | $346,699 | — | — | — |
| Cash & short-term investments | $5.0M | $148,891 | $74,366 | $2,430 |
| Net debt | −$4.6M | −$148,891 | −$74,366 | −$2,430 |
| Debt / equity | 0.03 | — | — | — |
| Debt / assets | 0.03 | — | — | — |
| Net debt / EBITDA | — | — | — | −2.63 |
| Current ratio | 81.93 | 35.54 | 5.21 | — |
| Quick ratio | 81.93 | 35.54 | 5.21 | — |
| Interest coverage | -496.6 | — | — | — |
| Working capital | $11.1M | $503,360 | $60,090 | $10,232 |
| Invested capital | $6.6M | $354,469 | −$14,276 | $7,802 |
| Tangible asset value | $11.2M | $503,360 | $60,090 | $10,232 |
| Net current asset value | $10.9M | $503,360 | $60,090 | $10,232 |
| Graham net-net per share | $3.25 | $0.10 | $0.04 | $0.00 |
| Capital allocation | ||||
| Capex / revenue | — | — | — | 0.0% |
| Capex / operating cash flow | — | — | — | 0.0% |
| Capex / depreciation | 0.00 | — | 0.00 | 0.00 |
| SG&A / revenue | — | — | — | 94.9% |
| Efficiency | ||||
| Days of inventory on hand | — | — | — | 50.5 |
| Inventory turnover | — | — | — | 7.22 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 2.54 |
| Average payables | $3,713 | $2,500 | $0 | — |
| Average inventory | — | — | $1,494 | $2,987 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from CURX's annual financial statements (latest annual report filed March 30, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CURX valuation and financial ratios
Curanex Pharmaceuticals earned a return on equity of −72.1% and a return on invested capital of −96.4% in fiscal 2025. It ended the year with $0.3 million of debt and $5.0 million in cash and short-term investments, a net cash position of $4.6 million.
See the CURX income statement, the CURX chart for price history, or the CURX stock overview for the latest quote and news.
CURX key metrics FAQ
What is Curanex Pharmaceuticals's return on equity?
Curanex Pharmaceuticals's return on equity (ROE) was −72.1% in fiscal 2025: net income of -$4.2 million on average shareholders' equity of $5.9 million.
What is Curanex Pharmaceuticals's ROIC?
Curanex Pharmaceuticals's return on invested capital was −96.4% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.
How much debt does Curanex Pharmaceuticals have?
Curanex Pharmaceuticals had total debt of $0.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.03 and more cash than debt.
What is Curanex Pharmaceuticals's free cash flow yield?
Curanex Pharmaceuticals generated -$10.5 million of free cash flow in fiscal 2025, a free cash flow yield of −111.9% on its market value at year-end ($9.4 million).
What is Curanex Pharmaceuticals's current ratio?
Curanex Pharmaceuticals's current ratio was 81.93 at the end of fiscal 2025: current assets were 81.93 times current liabilities.